A new investigation has raised fresh questions about a bestselling prescription medication to reduce stroke risk in those with the heart rhythm disorder known as atrial fibrillation. Published ...

Editor's Note: This post originally appeared at drjohnm.org. Before addressing the article's mistakes, it is laudable that mainstream media emphasizes the notion of weighing risks. All medical ...

The sometimes-fatal bleeding risk of Pradaxa, the popular anticoagulant and alternative to warfarin, has been a concern to the FDA since the drug was approved in 2010. FDA and clinical reviews have ...

Forbes contributors publish independent expert analyses and insights. I'm a medical journalist covering cardiology news. All the new oral anticoagulants are trying to displace warfarin, the ...

Boehringer Ingelheim is accusing The British Medical Journal (BMJ) of making “misleading statements” after the journal published an article and an editorial critical of the company’s pursuit of ...

Reports from Ireland and New Zealand may herald new concerns about the Riata defibrillator leads (St. Jude Medical) and dabigatran (Pradaxa). A poster presented at the European Society of Cardiology ...

Patients taking the new anti-clotting drug Pradaxa have a 33% higher risk of heart attack or severe symptoms of heart disease than do patients taking warfarin. The finding, from Cleveland Clinic ...

Treatment is reportedly the first new oral anticoagulant approved in the U.S. for over 50 years. FDA has approved Boehringer Ingelheim’s oral direct thrombin inhibitor Pradaxa® (dabigatran etexilate) ...

August 4, 2011 (Paris, France) — New reports of two elderly women faring badly when taking the novel anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) for stroke prevention in atrial ...

(Reuters) - The death of an elderly man from a massive brain hemorrhage after a routine fall suggests that bleeding complications from Boehringer Ingelheim's Pradaxa blood clot preventer are largely ...